Skip to main content

Table 2 Metabolic syndrome remission rate and metabolic profile

From: Excess body mass index loss predicts metabolic syndrome remission after gastric bypass

Follow-up time (months) 0 6 12 24 36 P
Patients n = 153 (100%) n = 153 (100%) n = 142 (93%) n = 112 (73%) n = 76 (50%) n.a
BMI (kg/m 2 ) 44.3 ± 0.5 32.7 ± 0.4***(a) 30.8 ± 0.4***(a) 31.2 ± 0.5***(a) 32.2 ± 0.7***(a) < 0.001
EBMIL (%) - 63.5 ± 1.5***(a) 73.4 ± 1.7***/**(a/b) 71.6 ± 1.8***/*(a/b) 67.8 ± 2.5***(a) < 0.001
Patients with MS 153 103 43 41 31 n.a
MS remission rate (%) 0.0 32.7***(a) 69.7***/***(a/b) 63.4%***/***(a/b) 59.2%***/***(a/b) (a),(b)p < 0.001
Fasting glycemia (mg/dL) 136.4 ± 4.8 95.0 ± 2.4***(a) 90.4 ± 1.1***(a) 93.7 ± 1.6***(a) 93.8 ± 1.9***(a) < 0.001
Systolic blood pressure (mm Hg) 147.2 ± 1.5 140.4 ± 1.7*(a) 138.3 ± 1.5***(a) 139.0 ± 1.7**(a) 143.9 ± 2.0 < 0.001
Diastolic blood pressure (mm Hg) 88.4 ± 1.0 82.5 ± 1.0***(a) 81.6 ± 1.0***(a) 81.9 ± 1.0***(a) 82.7 ± 1.4***(a) < 0.001
HDL (mg/dL) 45.5 ± 0.8 44.8 ± 1.0 52.0 ± 0.9***/***(a/b) 56.5 ± 1.0***/***/*(a/b/c) 56.4 ± 1.6***/***(a/b) < 0.001
Triglycerides (mg/dL) 171.7 ± 7.4 104.0 ± 3.2***(a) 94.5 ± 3.3***(a) 100.7 ± 5.0***(a) 104.6 ± 5.4***(a) < 0.001
Anti-diabetic treatment 101 (66.0%) 33 (22.8%)***(a) 28 (19.9%)***(a) 32 (28.6%)***(a) 25 (32.9%)***/*(a/c) (a)p < 0.001
(c)p = 0.046
Anti-hypertensive treatment 120 (78.4%) 59 (40.7%)***(a) 50 (35.7%)***(a) 41 (36.9%)***(a) 33 (43.4%)***(a) < 0.001
Anti-dyslipidemic treatment 66 (44.3%) 13 (9.0%)***(a) 13 (9.4%)***(a) 12 (10.8%)***(a) 12 (15.8%)***(a) < 0.001
  1. *p < 0.05; **p < 0.01; ***p < 0.001; (a) vs baseline; (b) vs 6 months; (c) vs 1 year. Kruskal–Wallis test (one-way ANOVA) with Dunn post hoc test for scale data and Chi Square test for ordinal data.